HC Wainwright Has Positive Outlook of Metagenomi Q4 Earnings

Metagenomi, Inc. (NASDAQ:MGX) – Research analysts at HC Wainwright upped their Q4 2024 earnings per share (EPS) estimates for Metagenomi in a research report issued on Thursday, November 21st. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($0.52) for the quarter, up from their previous forecast of ($0.69). HC Wainwright currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Metagenomi’s current full-year earnings is ($2.68) per share. HC Wainwright also issued estimates for Metagenomi’s Q1 2025 earnings at ($0.56) EPS, Q2 2025 earnings at ($0.59) EPS, Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.69) EPS and FY2025 earnings at ($2.48) EPS.

MGX has been the subject of a number of other research reports. BMO Capital Markets dropped their price target on Metagenomi from $22.00 to $17.00 and set an “outperform” rating for the company in a research note on Thursday, August 15th. Chardan Capital restated a “buy” rating and issued a $15.00 price objective on shares of Metagenomi in a report on Wednesday, November 20th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $15.50.

Metagenomi Stock Performance

NASDAQ MGX opened at $2.01 on Monday. Metagenomi has a fifty-two week low of $1.61 and a fifty-two week high of $12.74. The stock has a 50 day simple moving average of $2.03 and a two-hundred day simple moving average of $3.60.

Institutional Investors Weigh In On Metagenomi

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers purchased a new stake in Metagenomi in the second quarter worth about $26,000. BNP Paribas Financial Markets grew its stake in shares of Metagenomi by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock worth $28,000 after buying an additional 7,256 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Metagenomi in the 3rd quarter worth approximately $33,000. XTX Topco Ltd bought a new position in Metagenomi during the 2nd quarter valued at approximately $66,000. Finally, Resolute Advisors LLC raised its stake in Metagenomi by 165.0% during the second quarter. Resolute Advisors LLC now owns 26,500 shares of the company’s stock valued at $108,000 after buying an additional 16,500 shares during the last quarter.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.